436 related articles for article (PubMed ID: 26346369)
1. Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients.
Wu JL; Ma HY; Lu CY; Chen JM; Lee PI; Jou ST; Yang YL; Chang HH; Lu MY; Chang LY; Huang LM
J Microbiol Immunol Infect; 2017 Jun; 50(3):307-313. PubMed ID: 26346369
[TBL] [Abstract][Full Text] [Related]
2. Frequent occurrence of cytomegalovirus retinitis during immune reconstitution warrants regular ophthalmic screening in high-risk pediatric allogeneic hematopoietic stem cell transplant recipients.
Hiwarkar P; Gajdosova E; Qasim W; Worth A; Breuer J; Chiesa R; Ridout D; Edelsten C; Moore A; Amrolia P; Veys P; Rao K
Clin Infect Dis; 2014 Jun; 58(12):1700-6. PubMed ID: 24700657
[TBL] [Abstract][Full Text] [Related]
3. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
[TBL] [Abstract][Full Text] [Related]
4. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center.
Rowe RG; Guo D; Lee M; Margossian S; London WB; Lehmann L
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1275-1283. PubMed ID: 27090959
[TBL] [Abstract][Full Text] [Related]
6. Quantiferon-Cytomegalovirus assay: A potentially useful tool in the evaluation of CMV-specific CD8+ T-cell reconstitution in pediatric hematopoietic stem cell transplant patients.
Paouri B; Soldatou A; Petrakou E; Theodosaki M; Tsentidis C; Kaisari K; Oikonomopoulou C; Matsas M; Goussetis E
Pediatr Transplant; 2018 Aug; 22(5):e13220. PubMed ID: 29777573
[TBL] [Abstract][Full Text] [Related]
7. [Quantitative monitoring of blood cytomegalovirus after allogeneic hematopoietic stem cell transplantation and its clinical significance].
Qiu ZX; Wang MJ; Wang LH; Sun YH; Xu WL; Liu W; Ou JP; Dong YJ; Li Y; Liang ZY; Cen XN; Ren HY
Zhonghua Nei Ke Za Zhi; 2012 May; 51(5):371-5. PubMed ID: 22883336
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation.
Jeon S; Lee WK; Lee Y; Lee DG; Lee JW
Ophthalmology; 2012 Sep; 119(9):1892-8. PubMed ID: 22657564
[TBL] [Abstract][Full Text] [Related]
9. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
10. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
Huang XJ; Xu LP; Ren HY; Zhang YC; Guo NL; Lu DP
Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):766-9. PubMed ID: 12899755
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors Associated with Survival Following Ganciclovir Prophylaxis through Day +100 in Cytomegalovirus At-Risk Pediatric Allogeneic Stem Cell Transplantation Recipients: Development of Cytomegalovirus Viremia Associated with Significantly Decreased 1-Year Survival.
Klejmont LM; Mo X; Milner J; Harrison L; Morris E; van de Ven C; Cairo MS
Transplant Cell Ther; 2024 Jan; 30(1):103.e1-103.e8. PubMed ID: 37806447
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients.
Sahin DG; Gunduz E; Kasifoglu N; Akay OM; Us T; Gulbas Z
Adv Ther; 2013 Aug; 30(8):784-91. PubMed ID: 23959787
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
[TBL] [Abstract][Full Text] [Related]
14. Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation.
Schönberger S; Meisel R; Adams O; Pufal Y; Laws HJ; Enczmann J; Dilloo D
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1428-35. PubMed ID: 20399877
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
Panagou E; Zakout G; Keshani J; Smith C; Irish D; Mackinnon S; Kottaridis P; Fielding A; Griffiths PD
Transpl Infect Dis; 2016 Jun; 18(3):405-14. PubMed ID: 27061703
[TBL] [Abstract][Full Text] [Related]
16. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?
Kekre N; Tokessy M; Mallick R; McDiarmid S; Huebsch L; Bredeson C; Allan D; Tay J; Tinmouth A; Sheppard D
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1719-24. PubMed ID: 24099958
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation.
Jaing TH; Chang TY; Chen SH; Wen YC; Yu TJ; Lee CF; Yang CP; Tsay PK
Medicine (Baltimore); 2019 Jan; 98(4):e14172. PubMed ID: 30681583
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance.
Bilgrami S; Aslanzadeh J; Feingold JM; Bona RD; Clive J; Dorsky D; Edwards RL; Tutschka PJ
Bone Marrow Transplant; 1999 Jul; 24(1):69-73. PubMed ID: 10435738
[TBL] [Abstract][Full Text] [Related]
19. Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients.
Camacho-Bydume C; Mauguen A; Rodriguez-Sanchez MI; Klein E; Kernan NA; Prockop S; Boelens JJ; Papanicolaou GA; Cancio M
Cytotherapy; 2022 Apr; 24(4):428-436. PubMed ID: 35042670
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation.
Rustia E; Violago L; Jin Z; Foca MD; Kahn JM; Arnold S; Sosna J; Bhatia M; Kung AL; George D; Garvin JH; Satwani P
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1646-1653. PubMed ID: 27252110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
